Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Rockwell Medical, Inc. (RMTI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.6700-0.1100 (-6.18%)
At close: 04:00PM EDT
1.6400 -0.03 (-1.80%)
After hours: 06:50PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Slow Stochastic

Slow Stochastic

Previous Close1.7800
Open1.7800
Bid1.6300 x 2200
Ask1.7700 x 800
Day's Range1.6200 - 1.7800
52 Week Range1.6200 - 11.6600
Volume89,358
Avg. Volume50,617
Market Cap14.269M
Beta (5Y Monthly)1.09
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for RMTI

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Rockwell Medical, Inc.
    Daily – Vickers Top Insider Picks for 05/19/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • PR Newswire

    Rockwell Medical Provides First Quarter 2022 Financial and Operational Update

    Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today reported financial results and a business update for the three months ended March 31, 2022.

  • PR Newswire

    Rockwell Medical Submits Supplemental Data to FDA for IND Application for Phase 2 FPC Home Infusion Trial

    Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management, today announced that it provided the U.S. Food and Drug Administration (FDA) with the supplemental data, requested by the agency in December 2021, for the Company's pending Investigational New Drug (IND) application in support of a proposed Phase 2 clinical trial of Ferric Pyrophosphate Citrate (FPC) for the treatment of iron deficiency anemia and m

  • PR Newswire

    Rockwell Medical Announces 1-for-11 Reverse Stock Split

    Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management, today announced that its Board of Directors has approved a 1-for-11 reverse split of the Company's issued and outstanding common stock (the "Reverse Stock Split"). The Reverse Stock Split will become effective at 12:01 a.m. Eastern Time on May 13, 2022. Rockwell Medical's common stock is expected to begin trading on the Nasdaq Capital Market on a sp

Advertisement
Advertisement